Cystoscopy and endoscopic bladder procedure billing.
Our urology pillar guide already covers the core cystoscopy code family (52000–52332), the stone and ureteroscopy ladder (52351–52356), and the laterality and staging logic that governs both. This guide goes deeper on the two places cystoscopy billing actually loses money without anyone noticing: selecting the right transurethral bladder tumor resection (TURBT) code by size rather than by count, and coding bladder cancer surveillance cystoscopy — diagnosis, frequency, and the coverage gap most practices don't realize exists.
Key takeaways
- TURBT (52234, 52235, 52240) is coded by tumor size, not tumor count. One code per session, chosen by the single largest tumor resected — billing multiple lines because multiple tumors were removed is a common, avoidable overpayment risk.
- 52000 is bundled into the entire TURBT family with no override available in ordinary circumstances, while 52234/52235 nest into 52240 under a modifier indicator that does allow an override for genuinely separate tumor sites — those are two different edit types and worth knowing apart.
- Bladder cancer surveillance cystoscopy runs on AUA risk-stratified intervals, not a Medicare LCD. We checked; no active local coverage determination governs surveillance frequency, which means the payer's own medical policy — not just the guideline — decides what's payable.
- Surveillance diagnosis coding is a distinct category from a first-time hematuria workup. Z85.51 (personal history) plus the site-specific C67.x or D09.0 code the record actually supports is what a surveillance claim needs — not R31.9 carried forward out of habit.
TURBT: coding by size, not by tumor count
Transurethral resection of a bladder tumor is reported with one of three codes, and the deciding factor is the size of the largest tumor resected during the session — not how many separate tumors were removed. A surgeon who resects five small papillary tumors bills the same single code as one who resects a single tumor of the same maximum size. This is the single most common source of upcoding risk in the family: billing multiple TURBT lines because multiple tumors were treated, rather than one line reflecting the largest lesion.
| Code | Largest tumor size | Notes |
|---|---|---|
52234 | Small — up to 2 cm | Includes cystourethroscopy performed to locate and stage the tumor before resection. |
52235 | Medium — 2 cm to 5 cm | Same inclusion of the diagnostic look; the size threshold is what separates it from 52234. |
52240 | Large — over 5 cm | Also used for extensive or multiple large tumors where the largest exceeds 5 cm. |
The operative note has to state the size of the largest lesion resected in centimeters — not "multiple small tumors" or "extensive disease" without a measurement — because that number is the entire basis for code selection. A pathology report describing tumor fragments after resection is not a substitute for the surgeon's intraoperative size estimate, since fragmentation during resection routinely makes the specimen measure smaller than the lesion actually was in the bladder.
Bundling logic specific to this family
Two different NCCI edit types apply inside the TURBT family, and treating them as the same mistake costs claims either way.
52000 into any TURBT code. The diagnostic look that identifies and stages the tumor is inherent to the resection itself, and billing 52000 separately alongside 52234, 52235, or 52240 for the same session is one of the most reliably denied pairs in urology. Industry billing guidance consistently reports this edit as non-overridable in the ordinary case — confirm the current indicator for your specific pair before submission, since edit pairs are revised quarterly, but don't expect a modifier to rescue this one.
52234/52235 into 52240. This is a different kind of edit. CMS rebundled these three codes together, but 52234 and 52235 carry a modifier indicator of 1 relative to 52240 — meaning an override is possible where the documentation genuinely supports it. The narrow, well-established use case: tumors of different sizes resected at separate, distinct sites within the bladder, with the operative note independently documenting the size and location of each. That's a real exception, not a routine way to convert a single resection session into multiple billable lines, and it should be rare enough in your claims data that it draws a second look every time it appears.
Global period assignment for the TURBT codes affects whether an E/M visit in the days after resection is separately billable, and we could not independently confirm the current global-period days for 52234/52235/52240 against a primary CMS source during this build. ⚠️ Confirm the global period for these codes in the CMS Physician Fee Schedule Look-Up Tool before billing any post-procedure E/M, rather than assuming it matches a different endoscopic family.
Bladder cancer surveillance: diagnosis coding
A surveillance cystoscopy is coded differently from a first-time diagnostic cystoscopy for hematuria, and the difference is the diagnosis, not the procedure code. Once a patient has a bladder cancer history, the diagnosis field should reflect that history and the current disease status — not the symptom that originally triggered the workup years earlier.
| Clinical picture | Code |
|---|---|
| Active malignant neoplasm, site-specific | C67.0 trigone · C67.1 dome · C67.2 lateral wall · C67.3 anterior wall · C67.4 posterior wall · C67.5 bladder neck · C67.8 overlapping sites · C67.9 unspecified — use the specific site the record supports, not .9 by default |
| Carcinoma in situ of bladder | D09.0 |
| Neoplasm of uncertain behavior of bladder | D41.4 — the code most surveillance-phase non-muscle-invasive cases resolve to between active recurrences |
| Personal history, currently disease-free, on surveillance | Z85.51 — pair with the procedure code on a routine negative-surveillance cystoscopy |
Z85.51 alone, with no active neoplasm code, supports a routine surveillance visit where the prior cancer is not currently active — that's the correct pairing for the great majority of negative surveillance cystoscopies. A new or recurrent finding at surveillance shifts the diagnosis back to the active site-specific C67.x code or D09.0/D41.4, and the note has to say so explicitly; carrying Z85.51 forward on a visit where a recurrence was actually found and treated understates what happened clinically and can misalign the diagnosis with the procedure billed that same day.
Surveillance frequency: guideline versus coverage policy
We searched the CMS Coverage Database directly for a local coverage determination governing cystoscopy or bladder-tumor surveillance frequency and found none active. That's a meaningful gap: unlike urodynamics, which has LCD L34056 (CGS Administrators) and L33576 (Wellpoint Federal) on file, cystoscopy surveillance frequency is not set at the national or local Medicare coverage level. What actually governs interval is the American Urological Association's risk-stratified non-muscle-invasive bladder cancer (NMIBC) guideline.
| Risk group | Years 1–2 | Years 3–4 | Year 5+ |
|---|---|---|---|
| Intermediate risk | Every 3–6 months | Every 6–12 months | Annually |
| High risk | Every 3–4 months | Every 6 months | Annually |
The practical consequence of no LCD existing is that guideline adherence alone doesn't guarantee payment. A cystoscopy scheduled at exactly the interval the AUA guideline recommends can still be denied if the specific payer's own medical policy sets a different frequency cap or requires prior authorization above a certain visit count per year — particularly on Medicare Advantage and commercial plans, which build their own utilization-management policies independent of any LCD. Check the payer's medical policy for surveillance imaging and cystoscopy frequency before scheduling outside a standard annual cadence, not just the AUA interval table.
Do and don't
- Select the TURBT code from the single largest tumor size documented, in centimeters, in the operative note.
- Reserve the 52234/52235-into-52240 override for genuinely separate tumor sites with independently documented sizes.
- Code surveillance visits with Z85.51 plus the current disease status, not a historical symptom code.
- Check the specific payer's medical policy for surveillance frequency limits before scheduling outside a standard interval.
- Don't bill separate TURBT lines because multiple tumors were resected in one session.
- Don't append a modifier to bill 52000 alongside a TURBT code without confirming the current edit indicator first.
- Don't carry R31.9 or another symptom code forward on a patient now in confirmed surveillance status.
- Don't assume AUA-guideline timing alone clears a surveillance cystoscopy for payment on every plan.
Losing revenue on TURBT or surveillance cystoscopy denials?
We'll audit a sample of your recent cystoscopy and TURBT claims for size-based code selection, bundling errors, and surveillance diagnosis mismatches, and show what's recoverable.
Frequently asked questions
Can we ever bill CPT 52000 alongside a TURBT (52234-52240) for the same session?
No, in the ordinary case. The diagnostic look that locates the tumor is inherent to the resection itself, and 52000 is bundled into every code in the 52234-52240 family as a component step. Industry billing guidance consistently reports this specific edit as non-overridable, meaning no modifier changes the outcome. Confirm the current NCCI indicator for your exact code pair before submission regardless, since edit pairs are revised quarterly.
How do we code a TURBT when the surgeon resects tumors of different sizes in different parts of the bladder?
The general rule is one code per session, selected by the single largest tumor resected, regardless of how many separate tumors were removed. The narrow exception: 52234 and 52235 are bundled into 52240 under a modifier indicator of 1, which does permit an override, historically used when tumors of genuinely different sizes are resected at separate, distinct sites within the bladder and the operative note documents each site and size independently. That's a specific, well-documented exception, not a routine way to bill multiple lines for one resection session.
Is there a Medicare LCD that sets cystoscopy surveillance frequency for bladder cancer follow-up?
We searched the CMS Coverage Database directly and found no active local coverage determination specifically governing cystoscopy or bladder-tumor surveillance frequency. Surveillance intervals are set by the American Urological Association's risk-stratified NMIBC guideline, not by a national or local coverage policy. That doesn't mean frequency is unlimited from a payer's perspective: check the specific plan's own medical policy before scheduling a surveillance cystoscopy outside the standard interval, since a commercial or Medicare Advantage payer can still apply its own frequency cap even where no LCD exists.
Verify before billing. CPT is a registered trademark of the American Medical Association; codes here are paraphrased, not reproduced from the CPT Professional edition. CPT, HCPCS and ICD-10 codes, coverage policy, and bundling edits change, including annual code-set updates. This page reflects standard industry practice and is provided for general education — it is not a substitute for your own compliance review, your current payer contracts, or the current-year code sets. Confirm requirements against your specific payer mix before submitting claims.